MedWatch

Schizofrenia drug from Lundbeck approved by the FDA

The FDA has granted marketing authorization to the drug Abilify Maintena for the treatment of schizophrenia. The medicine is developed by Lundbeck and its partner company Otsuka.

Foto: Colourbox

Another day, another approval for The Danish pharmaceutical company Lundbeck.

As Thursday became Friday Lundbeck announced that the FDA had approved the company’s schizophrenia drug, Abilify Maintena. The approval comes less than 24 hours after the EMA awarded marketing authorization to another of Lundbeck’s drugs - the alcohol pill, Selincro.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier